Shares of Clarivate PLC (NYSE:CLVT – Get Free Report) have earned a consensus rating of “Reduce” from the eight ratings firms that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $3.0167.
CLVT has been the topic of a number of research analyst reports. The Goldman Sachs Group cut their target price on Clarivate from $2.90 to $2.60 and set a “neutral” rating on the stock in a research note on Thursday, July 30th. Wall Street Zen cut Clarivate from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Clarivate in a research report on Wednesday, June 24th. Citigroup lowered their target price on Clarivate from $2.80 to $2.50 and set a “neutral” rating on the stock in a research note on Thursday, July 30th. Finally, Barclays cut their price target on shares of Clarivate from $2.50 to $2.00 and set an “underweight” rating on the stock in a report on Thursday, July 30th.
Read Our Latest Analysis on Clarivate
Clarivate Price Performance
Clarivate (NYSE:CLVT – Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.18 by $0.01. Clarivate had a negative net margin of 13.84% and a positive return on equity of 9.15%. The company had revenue of $587.30 million during the quarter, compared to the consensus estimate of $589.73 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The firm’s revenue for the quarter was down 5.5% on a year-over-year basis. As a group, analysts forecast that Clarivate will post 0.67 EPS for the current fiscal year.
Insider Transactions at Clarivate
In related news, Director Kenneth L. Cornick bought 650,000 shares of Clarivate stock in a transaction dated Thursday, August 6th. The stock was purchased at an average cost of $1.86 per share, with a total value of $1,209,000.00. Following the transaction, the director directly owned 1,750,000 shares of the company’s stock, valued at approximately $3,255,000. The trade was a 59.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrew Miles Snyder sold 2,489,618 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $1.94, for a total transaction of $4,829,858.92. Following the transaction, the director directly owned 3,856,597 shares of the company’s stock, valued at $7,481,798.18. This represents a 39.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 22.88% of the stock is owned by insiders.
Institutional Trading of Clarivate
Large investors have recently bought and sold shares of the company. Personal CFO Solutions LLC purchased a new position in shares of Clarivate during the 1st quarter valued at $30,000. FreeGulliver LLC bought a new stake in Clarivate in the 1st quarter valued at about $30,000. Principal Financial Group Inc. purchased a new stake in Clarivate during the first quarter valued at about $32,000. M&T Bank Corp bought a new position in Clarivate during the fourth quarter worth about $34,000. Finally, Parallel Advisors LLC increased its stake in shares of Clarivate by 94.2% in the first quarter. Parallel Advisors LLC now owns 13,786 shares of the company’s stock worth $35,000 after purchasing an additional 6,687 shares in the last quarter. 85.72% of the stock is owned by hedge funds and other institutional investors.
About Clarivate
Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.
Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.
Featured Stories
- Five stocks we like better than Clarivate
- Deere Earnings: Has the Stock Outrun the Farm Cycle?
- BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish Setup
- 3 Dividend Stocks Raising Their Payouts as Investors Search for Growth and Income
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.
